ArticleDiscover oncology2025
Integrated analysis unraveling the immunologic and clinical prognostic values of synaptotagmin like 4 in pan-cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- miR-330-3p Inhibits the Development of Acute Myeloid Leukemia by Targeting SYTL4.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026Article
- Comprehensive analysis of SYTL4 differential expression and clinical implications in DLBCL.Frontiers in genetics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
SYTL4 (Synaptotagmin Like 4) encodes a protein of synaptotagmin like protein family, which participates in intracellular membrane trafficking. Currently, its role and mechanisms in cancer remain unveiled, necessitating additional comprehensive analysis across different types of cancer to assess its potential in diagnosis, prognosis, chemotherapy, and immunotherapy in cancer. In our study, the mRNA level, threshold for copy number alterations, segmentation of masked copy number alterations, and methylation of SYTL4 DNA were analyzed based on data from TCGA pan-cancer cohort. miRNA, TCPA, mutation and clinical data were analyzed to evaluate diagnostic and prognostic significances of SYTL4. Then the results were checked using cBioPortal and GEO database. The protein levels were analyzed and evaluated based on HPA database and Clinical Proteomic Tumor Analysis Consortium (CPTAC). Biological roles of SYTL4 in pan-cancer were explored by GSEA. We use multiple immune infiltration algorithms in TIMER2.0 and TISCH database to cross-verify the associations between SYTL4 expression and tumor immune microenvironment. Additionally, we depicted a pan-cancer survival map and explored the differences of gene expressions among cancers with different molecular subtypes. Through chemotherapy data from CellMiner, GDSC, CTRP database, we clarified the relationship between SYTL4 and drug resistance. Finally, we explored the chemical substances that affect SYTL4 expression through CTD database. This study systematically and comprehensively reveals the functions of SYTL4 and potential clinical diagnostic and therapeutic predictive values of SYTL4 in pan-cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.